vimarsana.com
Home
Live Updates
Galapagos announces start of Phase 2 study with selective TY
Galapagos announces start of Phase 2 study with selective TY
Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus
GLPG3667 is an investigational, novel, oral, reversible, and selective tyrosine kinase 2 inhibitor GLPG3667 is currently in development for the treatment of inflammatory and auto-immune diseases...
Related Keywords
Japan ,
Belgium ,
Mechelen ,
Region Flamande ,
Daniele Dambrosio ,
Marieke Vermeersch ,
Sandra Cauwenberghs ,
Van Gijsel ,
British Isles Lupus Assessment Group ,
Linkedin ,
Exchange Commission ,
Twitter ,
Composite Lupus Assessment ,
Cutaneous Lupus Erythematosus Disease Area ,
Severity Index Activity ,
Lupus Low Disease Activity State ,
Danieled Ambrosio ,
Therapeutic Area Head Immunology ,
Markets ,